Physician profile
Parul Jindal
NPI 1225322480
$4,675.78
in general payments reported to CMS, 2019-2025
40 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $300 · 2021: $203 · 2022: $184 · 2023: $587 · 2024: $1,215 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.41 |
| Education | $221.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $801.20 | 2022-2025 | Austedo Xr, Austedo Xr |
| Medtronic USA, INC. | $476.35 | 2019 | |
| Abbvie INC. | $405.54 | 2019-2025 | |
| Ucb, INC. | $325.03 | 2019-2025 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $288.86 | 2019-2024 | Ultomiris, Soliris |
| Sk Life Science, INC. | $282.80 | 2024 | Xcopri |
| Lilly USA, LLC | $228.30 | 2019-2024 | Emgality |
| Allergan, INC. | $219.58 | 2019-2020 | |
| Tanabe Pharma America, INC. | $161.45 | 2019-2024 | |
| Eisai INC. | $161.04 | 2023-2024 | |
| Greenwich Biosciences, INC. | $136.22 | 2019 | |
| Neurocrine Biosciences, INC. | $122.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $91.03 | 2019 | |
| Avanir Pharmaceuticals, INC. | $79.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.81 | 2023-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $65.54 | 2020-2024 | Vumerity, Tysabri |
| Amneal Pharmaceuticals LLC | $64.85 | 2019-2025 | Crexont |
| Averitas Pharma INC. | $57.90 | 2024 | Qutenza |
| Livanova USA, INC. | $57.24 | 2019-2020 | |
| Akcea Therapeutics, INC. | $51.27 | 2019 | |
| Pfizer INC. | $47.76 | 2023 | |
| Hospira, INC. | $47.51 | 2023-2025 | |
| Emd Serono, INC. | $44.52 | 2019 | |
| Genentech USA, INC. | $43.39 | 2023-2024 | Enspryng, Ocrevus |
| Acadia Pharmaceuticals INC | $37.31 | 2019 | |
| Genzyme Corporation | $31.27 | 2023 | |
| Argenx US, INC. | $29.04 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Octapharma USA, INC. | $28.86 | 2024 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $25.56 | 2021 | |
| Celgene Corporation | $24.74 | 2021 | |
| Lundbeck LLC | $22.64 | 2020 | |
| Adamas Pharmaceuticals, INC. | $22.30 | 2019 | |
| Impel Pharmaceuticals INC. | $20.94 | 2023 | Trudhesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.62 | 2025 | Caplyta |
| Ge Healthcare | $18.08 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $17.49 | 2023 | Firdapse |
| Acorda Therapeutics, INC | $15.91 | 2023 | Inbrija, Ampyra |
| Mdd US Operations, LLC | $13.17 | 2019 | |
| Avion Pharmaceuticals | $12.77 | 2023 | Dhivy |
| Amgen INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.